Michael A. Maldonado

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

Michael Schiff, Michael E. Weinblatt, R. Valente et al. · Annals of the Rheumatic Diseases · 2013 · 281 citations · Full text

Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

Michael E. Weinblatt, Michael Schiff, R. Valente et al. · Arthritis & Rheumatism · 2012 · 244 citations · Full text

Rheumatology 20, Rheumatology, Active Ra +15

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Jeremy Sokolove, Michael Schiff, Roy Fleischmann et al. · Annals of the Rheumatic Diseases · 2015 · 181 citations · Full text

The Role of Environmental Antigens in the Spontaneous Development of Autoimmunity in MRL- <i>lpr</i> Mice

Michael A. Maldonado, V.N. Kakkanaiah, Glen C. MacDonald et al. · The Journal of Immunology · 1999 · 125 citations

Deletion of Decay-Accelerating Factor (CD55) Exacerbates Autoimmune Disease Development in MRL/lpr Mice

Takashi Miwa, Michael A. Maldonado, Lin Zhou et al. · American Journal Of Pathology · 2002 · 95 citations · Full text

Inflammation, Immunogenetics, Autoimmune Disease Development +13